Last updated: 13.02.2014

Address: 352 Knotter Drive
Cheshire, CT 06410

Tel: 203-272- (2596)


Company description

Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare diseases. Alexion scientists are among the first in the world to unlock the therapeutic potential of inhibiting terminal complement, a group of proteins that play an important role in the body’s immune response and can destroy healthy tissue in certain patients.

Alexion discovered and developed Soliris® (eculizumab), a first-in-class terminal complement inhibitor, approved in the United States, Canada, European Union, Australia, and Japan as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH). Alexion is working urgently to investigate Soliris and additional biopharmaceuticals as treatments for patients with other rare and severe diseases, including cancer.

Products and services

Alexion Pharmaceuticals is dedicated to the development of therapies that address severe, ultra-rare and life-threatening diseases, including hematologic, kidney and neurologic diseases, transplant rejection, cancer and autoimmune disorders.



We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here